Home › Psoriatic Arthritis › Maryland › Baltimore
Psoriatic Arthritis clinical trials in Baltimore, MD
4 studies for Psoriatic Arthritis are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
RecruitingPhase 2
- Johns Hopkins Bayview Medical Center - Johns Hopkins Asthma & Allergy Center ( Site 5132), Baltimore
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
RecruitingPhase 3
- Clinical Site, Baltimore
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RecruitingPhase 3
- Johns Hopkins Hospital, Baltimore
About Psoriatic Arthritis
Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. Find out about symptoms and treatment.
More about Psoriatic Arthritis on MedlinePlus
Psoriatic Arthritis trials in other cities
- Houston, TX8 studies
- Charlotte, NC7 studies
- Parma, OH6 studies
- Tampa, FL6 studies
- Altoona, PA6 studies
- Philadelphia, PA6 studies
- Cleveland, OH5 studies
- Plantation, FL5 studies
- Clearwater, FL5 studies
- New York City, NY5 studies
- Milwaukee, WI5 studies
- San Diego, CA5 studies
Other studies in Baltimore
- Non-Small Cell Lung Cancer60 studies
- Breast Cancer47 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Cancer (all types)37 studies
- Colorectal Cancer31 studies
- Pancreatic Cancer31 studies
- Metastatic Cancer28 studies
- Obesity25 studies
- Heart Failure24 studies
- Bladder Cancer24 studies
- Stroke22 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.